<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between July 2000 and June 2003 a total of 21 patients with high-risk <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; n = 14), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; n = 6) or advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n = 1) were treated with an 188-Re labelled anti-CD66 antibody in the conditioning regimen for allogeneic stem cell transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>Radioimmunotherapy (RIT) was followed by standard full-dose conditioning with <z:chebi fb="0" ids="28901">busulfan</z:chebi> and high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> in 11 patients and reduced intensity conditioning regimen in 10 patients </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received an unmanipulated allogeneic graft from alternative donors (n = 15) or a HLA-identical familiy donor (n = 6) </plain></SENT>
<SENT sid="3" pm="."><plain>With a median follow up of 42 months (23-60) disease free survival for <z:hpo ids='HP_0000001'>all</z:hpo> patients was 43% </plain></SENT>
<SENT sid="4" pm="."><plain>Nine patients are still alive and in ongoing complete hematological remission </plain></SENT>
<SENT sid="5" pm="."><plain>The treatment related mortality was 28.6% (n = 6) and an equal number of patients died of relapsing disease within 30-385 days after transplantation </plain></SENT>
<SENT sid="6" pm="."><plain>Late organ toxicity, monitored for more than 1 year, was mild and not clinically relevant </plain></SENT>
<SENT sid="7" pm="."><plain>The combination of RIT with chemotherapeutic conditioning seems to be a therapy with an acceptable risk of treatment related morbidity and mortality as well as occurrence of severe <z:hpo ids='HP_0011009'>acute</z:hpo> GvHD </plain></SENT>
</text></document>